UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant to ~~TO SECTION~~ Section 13 ORor 15(d) OF

~~THE~~of ~~SECURITIES~~the ~~EXCHANGE~~Securities ~~ACT~~Exchange OFAct of 1934

Date of Report (~~date~~Date of earliest event reported): ~~September~~ 1October 15, 2015

~~SYNERGETICS~~Synergetics USA, ~~INC~~Inc.

(Exact name of registrant as specified in its charter)

Delaware	~~001-10382~~	20001-~~5715943~~10382		20-5715943
(State or other jurisdiction of incorporation)	~~(Commission File Number)~~	(~~I.R.S.~~Commission ~~Employer~~File ~~Identification No.~~Number)		(IRS Employer Identification No.)

3845 Corporate Centre Drive
O’Fallon, Missouri	63368
(Address of principal executive offices)	(Zip Code)

3845 Corporate Centre Drive, O’Fallon, Missouri 63368

(Address of principal executive offices, zip code)

(636) 939-5100

(Registrant'’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Introductory 1Note.~~01. Entry~~ ~~into a Material Definitive Agreement.~~

As previously disclosed, on September 1, 2015, Synergetics USA, Inc. (the “Company” or “Synergetics”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Valeant Pharmaceuticals International, a Delaware corporation (“VPI”) and Blue Subsidiary Corp., a Delaware corporation (the “Purchaser”). The Purchaser is a wholly owned subsidiary of VPI, which is a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., a Canadian corporation (“Valeant”). In accordance with the terms of the Merger Agreement, the Purchaser commenced a tender offer (the “Offer”) to purchase all outstanding shares of common stock, par value $0.001 (each, a “Share”) of Synergetics, at a price per Share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per Share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) (together, the “Offer Price”), upon the terms and subject to the conditions set forth in the Contingent Value Rights Agreement, dated September 16, 2015, by and between VPI and American Stock Transfer & Trust Company, LLC (the “CVR Agreement”), filed as Exhibit (a)(1)(G) to the Tender Offer Statement on Schedule TO (as amended or supplemented from time to time) filed by Valeant, VPI and the Purchaser with the Securities and Exchange Commission (“SEC”) on September 16, 2015.

OnItem ~~September~~ 1~~, 2015, Synergetics USA, Inc~~. ~~(the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Valeant Pharmaceuticals International (“Valeant”) and Blue Subsidiary Corp~~02., aTermination ~~wholly owned subsidiary~~ of ~~Valeant (“Merger Sub”), pursuant to which, among other things, Merger Sub will commence~~ a ~~tender~~Material ~~offer~~Definitive (the “Offer”) for all of the outstanding shares of common stock, par value $0.001 per share (“Common Stock”), of the Company, upon the terms and subject to the conditions set forth in the Merger Agreement.

~~Pursuant~~In toconnection ~~the~~with ~~Merger~~completion ~~Agreement,~~of ~~upon~~ the ~~terms and subject to the conditions thereof,~~ Merger ~~Sub~~(as ~~will~~defined ~~commence~~below) ~~the~~on ~~Offer within 10 business days of September 1~~October 15, 2015, ~~to acquire~~ all ofamounts ~~the~~due ~~outstanding~~and ~~shares~~owing ofunder ~~Common Stock at~~ the ~~following~~Amended ~~price,~~and Restated ~~each~~Loan ~~without interest thereon~~ and ~~subject~~Security toAgreement ~~any applicable tax withholding:~~ (~~i) $6.50 per share, net to~~ the ~~holder in cash (the~~ “~~Cash~~Credit ~~Consideration~~Agreement”), ~~plus~~dated ~~(ii)~~as ~~one~~of ~~contractual contingent value right per share (each~~December 16, ~~a “CVR”)~~2104, asby ~~set~~and ~~forth~~among inSynergetics ~~the~~and ~~Contingent~~certain ~~Value~~of ~~Rights~~its ~~Agreement~~subsidiaries, ~~which~~as ~~represents~~borrowers, ~~the~~and ~~right~~Regions toBank, ~~receive~~as uplender towere ~~two~~paid ~~contingent~~and ~~payments~~the ofCredit upAgreement towas terminated ~~$1.00~~ in ~~the~~accordance ~~aggregate~~with ~~upon~~its ~~the~~terms. ~~achievement~~The ofmaterial ~~certain~~terms ~~milestones,~~of ~~net to~~ the ~~holder~~Credit inAgreement ~~cash~~are ~~(the~~described ~~“Contingent~~in ~~Consideration”~~Synergetics’ ~~and~~Current ~~together~~Report ~~with~~on ~~the~~Form 8-K ~~Cash~~filed ~~Consideration,~~on ~~the “Offer Price”)~~December 17, ~~subject~~2014. ~~to,~~Such ~~and~~descriptions inare hereby ~~accordance~~incorporated ~~with,~~into ~~the~~this ~~terms~~Current ~~and~~Report ~~conditions~~by ~~of the Contingent Value Rights Agreement (described below)~~reference.

~~Concurrently~~Item ~~with~~2.01. ~~the~~Completion ~~execution and delivery~~ of ~~the~~Acquisition ~~Merger~~or ~~Agreement,~~Disposition ~~on September 1, 2015, the directors and certain officers~~ of the Company have entered into agreements with Valeant and Merger Sub committing to not transfer their respective shares of the Common Stock and, subject to certain exceptions, tender their shares in the OfferAssets.

~~Following~~The ~~the~~disclosures ~~consummation~~under of the ~~Offer,~~Introductory ~~subject~~Note toand ~~the~~Item 3.01 ~~satisfaction~~are oreach ~~waiver~~incorporated ofherein ~~certain~~by ~~conditions~~reference. ~~set~~The ~~forth~~Offer inexpired ~~the~~at ~~Merger Agreement~~11:59 p.m., New ~~including~~York ~~Valeant’s~~City ~~execution~~time, ofon ~~the Contingent Value Rights Agreement~~October 14, ~~Merger~~2015 ~~Sub will merge with and into the Company~~ (the “~~Merger~~Expiration Time”), ~~and the Company will survive~~ as ascheduled ~~wholly~~and ~~owned~~was ~~subsidiary~~not ~~of Valeant~~extended. ~~The~~American ~~Merger~~Stock ~~will~~Transfer & beTrust ~~effected~~Company, ~~pursuant~~LLC, tothe ~~Section~~depositary ~~251(h)~~for of the ~~Delaware~~Offer ~~General Corporation Law~~ (the “~~DGCL~~Depositary”), ~~without~~has ~~any~~advised ~~stockholder~~VPI ~~vote~~and the ~~required~~Purchaser ~~with~~that ~~respect~~as ~~to the adoption~~ of the ~~Merger~~Expiration ~~Agreement.~~Time ~~At the effective time of the Merger~~18,271,479 ~~the~~Shares ~~shares~~were ofvalidly ~~Common~~tendered ~~Stock~~into and not ~~purchased~~properly bywithdrawn ~~Merger~~from ~~Sub pursuant to~~ the Offer, ~~(other~~representing ~~than~~approximately ~~shares~~72.1% of ~~Common~~the ~~Stock owned~~25, ~~directly or indirectly~~336,321 byoutstanding ~~Valeant,~~Shares ~~Merger~~as ~~Sub~~of orthe ~~any~~Expiration ~~wholly~~Time. ~~owned subsidiary of Valeant~~Additionally, ~~shares~~the Depositary ofhas ~~Common~~advised ~~Stock~~VPI ~~held~~and by the ~~Company~~Purchaser ~~and~~that ~~shares~~as of ~~Common~~the ~~Stock~~Expiration ~~owned~~Time byNotices ~~stockholders~~of ~~who~~Guaranteed ~~have~~Delivery ~~properly~~had ~~exercised~~been ~~any~~delivered ~~available~~with ~~rights~~respect ofto ~~appraisal~~2,978,556 ~~under~~additional ~~Section~~Shares, ~~262~~representing approximately 11.8% of the ~~DGCL)~~outstanding ~~will~~Shares beas ~~automatically~~of ~~converted into~~ the Expiration ~~right~~Time. toThe ~~receive~~Purchaser anhas ~~amount~~accepted infor ~~cash~~payment ~~per~~all ~~share~~Shares ofvalidly ~~Common~~tendered ~~Stock~~into ~~equal to~~ the Offer ~~Price, without interest thereon~~ and ~~subject~~not toproperly ~~any applicable tax withholding~~withdrawn.

InOn October 15, ~~addition~~2015, inthe ~~connection~~Purchaser merged with ~~the~~and ~~transactions~~into ~~contemplated~~Synergetics by (the “Merger ~~Agreement~~”), ~~each~~with ~~option~~Synergetics toas ~~purchase~~the ~~shares~~surviving ofcorporation ~~Common Stock~~ and ~~share~~a ofwholly ~~restricted~~owned ~~Common~~subsidiary ~~Stock~~of VPI (the “~~Restricted~~Surviving ~~Share~~Corporation”). ~~that~~The isMerger ~~outstanding~~was ~~immediately~~governed ~~prior~~by Section 251(h) toof the ~~effective~~Delaware ~~time~~General ofCorporation Law (the ~~Merger~~“DGCL”), ~~will~~with ~~become~~no ~~fully~~stockholder ~~vested~~vote as of ~~the~~Synergetics ~~effective~~required ~~time~~to ofconsummate the Merger. At the effective time of the Merger, ~~all~~(the ~~outstanding~~“Effective ~~options~~Time”), ~~will~~each ~~be cancelled~~outstanding Share, ~~and~~other ~~the~~than ~~holders~~(i) Shares ofheld ~~such~~by ~~options~~Synergetics ~~will receive at,~~ or asowned ~~soon~~by ~~as practicable following~~Valeant, ~~the~~VPI ~~effective~~or ~~time of~~ the ~~Merger~~Purchaser, ~~the~~or ~~following:~~by ~~(i)~~any andirect ~~amount~~or ofindirect ~~cash~~wholly ~~equal~~owned tosubsidiary ~~(A) the total number~~ of ~~shares~~Synergetics, ofVPI ~~Common~~or ~~Stock subject to the option multiplied by (B) the excess~~Valeant, ifall ~~any,~~ of ~~(x)~~which ~~the~~will ~~Cash~~be ~~Consideration~~cancelled ~~over~~and ~~(y)~~will ~~the~~cease ~~applicable~~to ~~per-share~~exist ~~exercise price of such option,~~ and (ii) Shares ~~one~~owned ~~CVR~~by ~~for~~stockholders ~~each share~~ of ~~Common~~Synergetics ~~Stock~~who ~~underlying~~properly ~~such~~exercise ~~option, in each case without interest~~ and ~~subject~~perfect totheir ~~any~~appraisal ~~applicable~~rights ~~tax~~under ~~withholding.~~Section 262 ~~At the effective time~~ of the ~~Merger~~DGCL, ~~all~~if ~~outstanding~~any, ~~Restricted~~was ~~Shares will~~converted beinto ~~cancelled, and~~ the ~~holders~~right ofto ~~such Restricted Shares will~~ receive ~~at, or as soon as practicable following, the effective time of the Merger, the following: (i)~~ an amount of cash equal to the ~~Cash~~Offer ~~Consideration for each Restricted Share held by such holder, and (ii) one CVR for each Restricted Share held by such holder, in each case without interest and subject to any applicable tax withholding~~Price.

The ~~Merger~~foregoing ~~Agreement~~description ~~includes~~of ~~customary~~the ~~representations~~Offer, ~~warranties~~the Merger and ~~covenants by~~ the ~~respective~~Merger ~~parties.~~Agreement ~~The~~and ~~Company has agreed to operate its business in~~ the ~~ordinary~~transactions contemplated ~~course~~thereby ofis ~~business~~not complete and is ~~subject~~qualified toin ~~customary~~its ~~operating~~entirety ~~restrictions,~~by ~~until~~reference ~~the~~to ~~earlier of~~ the ~~termination of the~~ Merger Agreement, orwhich ~~the~~was ~~consummation~~filed ~~of the Merger~~ as ~~more fully set forth in the Merger Agreement~~Exhibit 2.1 ~~The Company has also agreed not~~ to ~~solicit or initiate discussions with third parties regarding other proposals to acquire~~ the ~~Company,~~Current ~~subject~~Report toon ~~certain~~Form 8-K ~~exceptions~~filed ~~for~~by the Company ~~in connection~~ with the ~~exercise~~SEC ofon ~~the~~September 2, ~~fiduciary~~2015 ~~duties of the Board of Directors of the Company. The Merger Agreement includes certain termination provisions for both the Company~~ and ~~Valeant~~which ~~and~~is ~~provides~~incorporated ~~that,~~herein inby ~~connection with the termination of the Merger Agreement under certain specified circumstances, the Company may be required to pay Valeant a termination fee of $6~~reference.2 ~~million.~~

~~Consummation~~On ofOctober 15, ~~the~~2015, ~~Offer~~Valeant isissued ~~subject~~press toreleases announcing ~~various~~both ~~conditions, including among others,~~ the expiration orand ~~termination~~results of ~~applicable waiting periods under any competition law, including under~~ the ~~United States Hart-Scott-Rodino Antitrust Improvements Act of 1976~~Offer, ~~as amended,~~ and ~~other customary conditions, each as more fully described in~~ the ~~Merger Agreement. In addition, it is also a condition to the~~ consummation of the ~~Offer that the number of shares of Common Stock validly tendered and not withdrawn pursuant to the Offer, together with the shares of Common Stock, if any, then owned by Valeant,~~ Merger ~~Sub~~thereafter. orCopies ~~any~~ of ~~their respective subsidiaries, constitutes at least a majority of~~ the ~~total~~press ~~number~~releases ofare ~~outstanding~~filed ~~shares~~as ofExhibits 99.1 ~~Common Stock on a fully diluted basis (which assumes conversion or exercise of all derivative securities regardless of the conversion or exercise price, the vesting schedule or other terms~~ and ~~conditions thereof) as of the expiration date of the Offer~~99.2 ~~Neither~~hereto ~~the~~and ~~Offer~~are ~~nor~~incorporated ~~the~~by ~~Merger~~reference ~~is subject to a financing condition~~herein.

~~Contingent~~Item ~~Value~~3.01. ~~Rights~~Notice ~~Agreement~~of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

OnAs ora ~~prior~~result toof the ~~Offer~~transactions ~~closing~~described ~~date,~~in ~~Valeant~~Item 2.01 ~~will~~of ~~enter~~this ~~into~~Current aReport ~~Contingent~~on ~~Value~~Form ~~Rights~~8-K, ~~Agreement~~which ~~(the~~are ~~“Contingent~~incorporated ~~Value~~herein ~~Rights~~by ~~Agreement”)~~reference, ~~with~~the Company (a) notified ~~duly~~the ~~qualified~~NASDAQ ~~rights~~Stock ~~agent~~Market ~~selected~~LLC by(“NASDAQ”) ~~Valeant.~~of ~~Each CVR represents~~ the ~~right~~consummation ~~to receive contingent payments~~ of ~~up to $1.00 in cash in~~ the ~~aggregate,~~Merger ~~without~~and ~~interest,~~(b) requested ifthat ~~the~~NASDAQ ~~following milestones are achieved:~~ (i) suspend ~~$0.50~~trading ~~per~~of ~~share~~the inShares ~~cash~~effective ~~payable~~as ~~upon sales~~ of the ~~Company’s~~close ~~ophthalmology~~of ~~products~~trading ~~achieving $55 million~~ on aOctober 15, ~~trailing four calendar quarter basis prior to June 30~~2015, ~~2018;~~ and (ii) file ~~$0.50~~with ~~per~~the ~~share~~SEC ina ~~cash~~Form 25 ~~payable~~Notification ~~upon sales~~ of ~~the~~Removal ~~Company’s~~from ~~ophthalmology~~Listing ~~products~~and/or ~~achieving~~Registration ~~$65 million on a trailing four calendar quarter basis prior~~ to ~~June~~delist ~~30,~~and ~~2018,~~deregister ~~with~~the aShares ~~pro-rata~~under ~~portion~~Section 12(b) ~~payable~~of ~~for~~the ~~net~~Securities ~~sales~~Exchange ~~above~~Act ~~$55~~of ~~million~~1934, ~~but~~as ~~less~~amended ~~than $65 million during~~ (the ~~four~~“Exchange ~~calendar quarter period ending June 30, 2108~~Act”). The Company ~~right~~also intends to ~~the~~file ~~Contingent~~a ~~Consideration~~Form 15 aswith ~~evidenced by~~ the ~~Contingent~~SEC ~~Value~~requesting ~~Rights~~that ~~Agreement~~the isCompany’s areporting ~~contractual~~obligations ~~right~~under ~~only~~Sections 13 and ~~will~~15(d) ~~not~~of ~~be transferable, except in~~ the ~~limited~~Exchange ~~circumstances~~Act ~~specified~~be ~~in the Contingent Value Rights Agreement~~suspended.

~~The~~Item ~~foregoing~~3.03. ~~descriptions~~Material ofModification ~~the Merger Agreement and Contingent Consideration~~ to ~~be paid pursuant to the Contingent Value~~ Rights ~~Agreement are not complete descriptions~~ of ~~all~~Security ~~of the parties’ rights and obligations under the agreements and are qualified in their entireties by reference to the Merger Agreement, a copy of which is filed as Exhibit 2~~Holders.1 to this Current Report on Form 8-K, and the Form of Contingent Value Rights Agreement, a copy of which is filed as Exhibit B to the Merger Agreement filed as Exhibit 2.1 to this Current Report on Form 8-K, each of which is incorporated herein by reference.

~~Item~~As 8a result of the Merger and at the Effective Time of the Merger, each Share issued and outstanding immediately prior to the Effective Time, other than (i) any Shares held in the treasury of Synergetics and each Share owned by the Purchaser, VPI or any direct or indirect wholly owned subsidiary of VPI or by Synergetics immediately prior to the Effective Time which have been canceled without any conversion thereof and no payment or distribution will be made with respect thereto and (ii) any Shares owned by Synergetics’ stockholders who properly exercise and perfect their appraisal rights under Section 262 of the DGCL, if any, were automatically cancelled and converted into the right to receive an amount of cash equal to the Offer Price.~~01. Other~~ ~~Events~~At the Effective Time, the holders of such Shares ceased to have any rights as stockholders of Synergetics (other than their right to receive the Offer Price).

OnThe ~~September~~information 2,set ~~2015,~~forth ~~the~~in ~~Company issued a press release announcing~~ the ~~execution~~Introductory ofNote, ~~the~~Item 2.01, ~~Merger~~Item 3.01 ~~Agreement~~and Item 5.01 ~~A copy~~ of ~~the press release is filed as Exhibit 99.1 to~~ this Current Report on Form 8-K ~~and~~ is incorporated herein by reference.

Item 95.01. ~~Financial~~ ~~Statements~~Changes ~~and~~in ~~Exhibits~~Control of Registrant.

As a result of the Purchaser’s acceptance of Shares validly tendered and not properly withdrawn pursuant to the Offer prior to the Expiration Time and the consummation of the Merger pursuant to Section 251(dh) ~~Exhibits~~ of the DGCL, a change in control of Synergetics has occurred. Upon the consummation of the Merger, Synergetics became a wholly owned subsidiary of VPI.

Exhibit No.	Description of Exhibit.
2.1	Agreement and Plan of Merger, dated as of September 1, 2015, by and among Valeant Pharmaceuticals International, Blue Subsidiary Corp. and Synergetics USA, Inc.
99.1	Press Release issued by Synergetics USA, Inc., dated September 2, 2015.

The aggregate consideration required to purchase all the issued and outstanding Shares validly tendered and not withdrawn pursuant to the Offer, acquire all the remaining issued and outstanding Shares pursuant to the Merger and to cancel or acquire the underlying Shares with respect to all outstanding options and equity awards granted by Synergetics is approximately $169 million in upfront cash payments (such payments to be paid out of a combination of cash on hand and borrowings under available credit facilities of Valeant and VPI), without giving effect to related transaction fees and expenses, and 26,664,675 CVRs, which represent the right to receive up to a maximum aggregate amount of $26,664,675 if specified sales milestones are achieved within the agreed upon time period, upon the terms and subject to the conditions set forth in the CVR Agreement.

~~SIGNATURES~~The information set forth in Item 2.01, Item 3.01, Item 3.02 and Item 5.02 of this Current Report on Form 8-K is incorporated herein by reference.

~~Pursuant~~Item to5.02. ~~the~~Departure ~~requirements~~ of ~~the~~Directors ~~Securities~~or ~~Exchange~~Certain ~~Act~~Officers; Election of ~~1934,~~Directors; ~~the~~Appointment ~~registrant~~of ~~has~~Certain ~~duly~~Officers; ~~caused~~Compensatory ~~this~~Arrangements ~~report~~of toCertain ~~be signed on its behalf by the undersigned hereunto duly authorized~~Officers.

~~Dated: September~~Pursuant 2to the terms of the Merger Agreement, ~~2015~~at the Effective Time, the directors and officers of the Purchaser immediately prior to the Effective Time became the directors and officers of Synergetics following the Effective Time. Accordingly, at the Effective Time, each of Mr. David M. Hable, Mr. Lawrence C. Cardinale, Ms. Juanita H. Hinshaw, Mr. D. Graeme Thomas and Mr. Robert H. Blankemeyer resigned as directors of Synergetics and any committee thereof. Each director resigned in accordance with the Merger Agreement, and no director resigned because of any disagreement with the Company on any matter relating to Synergetics’ operation, policies, or practices. Also at the Effective Time, Mr. David M. Hable, the President and Chief Executive Officer, Ms. Pamela Boone, the Executive Vice President and Chief Financial Officer, Mr. Michael Fanning, Vice President of Domestic Sales, Mr. Jason Stroisch, Vice President, Marketing & Technology and Ms. Joan Kraus, Vice President, Regulatory Affairs / Quality Assurance, ceased being executive officers of Synergetics.

~~SYNERGETICS~~At ~~USA~~the Effective Time, ~~INC~~Mr. J. ~~(Registrant)~~Michael ~~By:~~Pearson ~~/s/~~assumed ~~David~~the M.role ~~Hable~~of ~~Name:~~director, ~~David~~President Mand Chief Executive Officer of Synergetics, Mr. Robert L. ~~Hable~~Rosiello ~~Title:~~assumed the role of director, Executive Vice President and Chief ~~Executive~~Financial Officer of Synergetics, Mr. Robert R. Chai-Onn assumed the role of director Executive Vice President, General Counsel and Corporate Secretary of Synergetics and Ari S. Kellen assumed the role of Executive Vice President of Synergetics. Information about Messrs. Pearson, Rosiello, Chai-Onn and Kellen is contained in Schedule A to the Offer to Purchase, dated September 16, 2015, filed by Valeant, VPI and the Purchaser as Exhibit (a)(1)(A) to the Tender Offer Statement on Schedule TO, originally filed with the SEC on September 16, 2015, as subsequently amended, which information is incorporated herein by reference.

Item 5.03. Amendments to Certificate of Incorporation or Bylaws; Change of Fiscal Year.

Pursuant to the Merger Agreement, at the Effective Time, Synergetics’ Amended and Restated Certificate of Incorporation was amended and restated (the “Amended Certificate of Incorporation”) and Synergetics’ Amended and Restated Bylaws were amended and restated (the “Amended By-laws”).

The Amended Certificate of Incorporation and the Amended By-laws are attached hereto as Exhibits 3.1 and 3.2, respectively, and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed as part of this Current Report on Form 8-K:


Exhibit No.		Description

2.1		Agreement and Plan of Merger, dated as of September 1, 2015, by and among Valeant Pharmaceuticals International, Blue Subsidiary Corp. and Synergetics USA, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Synergetics with the SEC on September 2, 2015).

3.1		Amended and Restated Certificate of Incorporation of Synergetics USA, Inc.*

3.2		Amended and Restated Bylaws of Synergetics USA, Inc.*

99.1		Press Release issued by Valeant Pharmaceuticals International, Inc., dated October 15, 2015 (incorporated by reference to Exhibit (a)(5)(F) to Schedule TO/A filed by Valeant, VPI and the Purchaser with the SEC on October 15, 2015).

99.2		Press Release issued by Valeant Pharmaceuticals International, Inc., dated October 15, 2015.*

*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	SYNERGETICS USA, INC.

Date: October 15, 2015	By:	/s/ Robert R. Chai-Onn
	Name:	Robert R. Chai-Onn

	Title:	Executive Vice President, General Counsel and Corporate Secretary

EXHIBIT INDEX


Exhibit No.		Description

2.1		Agreement and Plan of Merger, dated as of September 1, 2015, by and among Valeant Pharmaceuticals International, Blue Subsidiary Corp. and Synergetics USA, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Synergetics with the SEC on September 2, 2015).

3.1		Amended and Restated Certificate of Incorporation of Synergetics USA, Inc.*

3.2		Amended and Restated Bylaws of Synergetics USA, Inc.*

99.1		Press Release issued by Valeant Pharmaceuticals International, Inc., dated October 15, 2015 (incorporated by reference to Exhibit (a)(5)(F) to Schedule TO/A filed by Valeant, VPI and the Purchaser with the SEC on October 15, 2015).

99.2		Press Release issued by Valeant Pharmaceuticals International, Inc., dated October 15, 2015.*

*	Filed herewith

Filing Compare · SYNERGETICS USA INC